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INTRODUCTION 
 
 
 
Acute Lymphoblastic Leukemia [ALL] is the most common 
childhood malignancy. It accounts for one fourth of all childhood cancers 
and approximately 75% of all cases of childhood leukemia [1]. Before the 
advent of effective chemotherapy in 1960s ALL is usually a fatal disease 
.With modern intensive protocols at least in the developed countries 70%-
80% of children with ALL are now being the long term survivors. However 
this is not the case in developing countries where 80% of children with ALL 
reside. Approximately 8000 cases of childhood ALL diagnosed in each year 
in India.[3] Only 25% receive appropriate treatment. Studies from India 
have shown that 40%to 60% of patients treated in a paediatric oncology 
centre on an affordable protocol with manageable toxicities can be 
cured.[27,37,45] 
 There are several reasons for these poor results including poverty, 
lack of awareness, lack of access to adequate medical care, lack of 
adequately trained personnel and competent oncology units. These factors 
lead to delayed and sometimes improper diagnosis, delayed referrals, poor 
compliance, inadequate or inappropriate therapy and poor outcome 
 
  
EPIDEMIOLOGY: The incidence of childhood ALL is approximately 3-4 
cases per 100,000 children under the age of 15 years [20] .It is most 
common between ages of 1 and 5 years with a peak at 3-4 years [1,3]. The 
incidence of ALL is higher in boys than in girls 
 
 
ETIOLOGY: The etiology of   ALL is not known in virtually all cases 
[2].Environmental factors such as electro magnetic radiation, ionizing 
radiation, pesticides and infectious agents such as Epstein Barr virus have 
been implicated. Genetic disorders predisposing to leukemia include trisomy 
21, congenital immunodeficiency, ataxia-telangiectasia, bloom syndrome 
and fanconi’s anemia. Siblings of children with ALL have a 2-4 fold 
increased risk of developing ALL than do children in the general population. 
The risk is being high among homozygotic twins especially during the first 
few years of life. 
 
 
 
            
 
FIGURE 1 - CYTOLOGY FROM TESTICULAR TUMOUR 
SHOWING ATYPICAL LYMPHOBLASTIC INFILTRATION  
(PAP STAIN - H 609/06) 
 
 
 
FIGURE 2 - HYPERLEUKOCYTOSIS IN PERIPHERAL SMEAR IN 
ALL. LEISHMAN STAIN X 100 H 926/05 
 
 
 
CLASSIFICATION: 1.Morphological: 
 
 
 
Cytological 
features 
L1 L2 L3 
Cell size  Small cells 
predominate 
Large, 
heterogeneous in 
size 
Large and 
homogeneous 
Amount of 
Cytoplasm 
Scanty Variable, often 
mod. Abundant 
Moderately 
abundant 
Nucleoli Not visible, or 
small and 
inconspicuous 
One or more 
present, often 
large 
 
One or more 
present often 
prominent 
Nuclear 
Chromatin 
Homogeneous 
in any one case
Variable, 
heterogeneous in 
any one case 
Finely stippled 
and 
homogeneous  
Nuclear Shape Regular, 
occasional 
clefting or 
indentation 
Irregular, clefting 
and indentation 
Regular oval to 
round 
of cytoplasm Variable 
 
Variable 
 
Intensely 
basophilic 
Cytoplasmic 
vacuolation 
Variable 
 
Variable 
 
Prominent  
 
Cytochemistry: 
  
 Sharma JS and Mohindroo S had found that the concordance with 
morphology alone was 75% which improved to 92% when cyto chemistry is 
included  
            
    
FIGURE 3 - MYELOBLASTS WITH MULTIPLE AUER RODS IN 
AML M3 LEISHMAN STAIN X 1000 H 1069/05. 
 
            
 
 
FIGURE 4 - ALL L2 BLAST CELLS VARIES IN SIZE AND 
AMOUNT OF CYTOPLASM. LEISHMAN STAIN X 450 H 1258/06. 
 The stains commonly used are  
1. Myeloperoxidase (MPO) 2.Sudan Black B (SB] 3.Non specific 
esterase (NSE] 4.Specific esterase 5. PAS  
          Lymphoblasts are acid Schiff positive in block pattern. The 
myeloblasts are PAS negative but myeloperoxidase and Sudan block 
positive. The monocytes are nonspecific esterase positive. The terminal 
deoxy transferase is positive in 95% of the cases of lymphoblasts and only in 
5% of the myeloblasts  
           Snower DP et al, [65] in their study of 51 cases found that the  
sensitivity and specificity of the PAS stain alone for lymphoblastic leukemia 
was 52% (15 true positives of 29) and 81% (four false positives), 
respectively. The sensitivity of a cytochemical-staining combination of PAS 
positivity and myeloperoxidase, Sudan black B, and alpha-naphthyl butyrate 
esterase negativity in defining cases of lymphoblastic leukemia remained at 
52%; however, the specificity of this combination for lymphoblastic 
leukemia was 100% (no false positives). Thus, a positive PAS stain, in 
combination with negative myeloperoxidase, Sudan black B, and alpha-
naphthyl butyrate esterase stains, continues to have a diagnostic role in the  
 
         
 
FIGURE 5 - MYELO PEROXIDASE STAIN SHOWING NEGATIVE 
STAINING IN CYTOPLASM IN ALL X 450 H 350/05. 
 
 
 
FIGURE 6 – SUDAN BLOCK B STAIN SHOWING INTENSE 
BLACK GRANULAR STAINING IN CYTOPLASM IN  
AML M3 X 450 H 1069/05 
 
distinction between lymphoblastic and myeloblastic leukemia, and greater 
immunologic sophistication serves to support this position. 
IMMUNOLOGIC SUB TYPING: 
      It is usually based on reactivity with a panel of lineage –associated 
antibodies [1,8].About 85% of ALL are derived from progenitor cells.15% 
from T cells,1% from B cells [5] 
Small percentage with both lymphoid and myeloid markers [1,8] 
Subtype Antigen expression 
Early pre -B CCD22,CD79a,CD19+CD22Cig-
[mu] sIg- 
Pre B cell cIg + [mu] 
B cell SIg+, SIg [kappa], SIg [lamda] 
T cell   CCD23+,CD7+,CD5+, CD2+,CD3+ 
 
[CCD22-cytoplasmic CD22, CIg—cytoplasmic immunoglobin 
SIg- surface immunoglobin, mu- mu heavy chain protein, Kappa- kappa 
light chain protein, lambda-lambda light chain protein] 
             
 
 
CYTOGENETIC ABORMALITIES 
Genetics of leukemia:  
  Genetic alterations are at the base of all leukemias. Specific 
chromosomal changes can be identified now in more than 90% of the ALL 
cases [1]. Most of them are reciprocal translocations. These abnormalities 
correlate with the blast cell biologic properties, clinical features and have a 
correlation with the prognosis of the disease. Methods to diagnose genetic 
alterations are as follows 
1. cytogenetics 2. fluorecent in situ hybridization 3.flow cytometry-
measures total cell content, which    correlates with chromosomal number.4  
Reverse Transcriptase Polymerase Chain Reaction [RT-PCR]. It is a very 
sensitive and specific test to detect minimal residual disease and relapse 
      Importance of cytogenetic and molecular cytogenetic studies evaluation 
[34,35]  : 
1. Diagnosis and risk classification- allows better correlation of tumor 
characteristics with clinical behavior 
2. Specific therapy-e.g. ATRA for t [15,17] inM3 has provided the first 
example of therapy directed at the underlying molecular defect 
3. Monitoring minimal residual disease: the exquisite sensitivity of RT-
PCR assays has provided the ability to detect residual leukemia at 
previously unattainable levels. 
4. Diagnosis of relapse: RT-PCR helps too detect relapses in patients 
with known molecular lesions before morphological relapses 
        
Hyperdiploidy, Trisomies of 4, 10 chromosomes and translocation t [12,21] 
favor good prognosis. Hypodiploidy, translocations t [9,22], t[4,11] favor  
poor prognosis [21] 
CLINICAL MANIGESTATIONS: 
    The most common symptoms and signs are usually the manifestations of 
the underlying anemia [pallor, fatigue], thrombocytopenia [petechiae, 
purpura and bleeding] and neutropenia [fever and infections] Extramedullary 
disease commonly present as lymphadenopathy and hepato-splenomegaly in 
>60% of case [20]. 
Adverse factors include: male sex, age less than 1 year and more than 
9 years, count more than 50,000 cells per cu mm, L3 morphology, CNS 
disease, mediastinal mass, hypoploidy, Philadelphia chromosome and t 
(4;11), persistence of blast on day 7 or 14 after start of therapy. Advanced 
age and high WBC count at the time of diagnosis have a significantly 
adverse prognosis. Unfavorable cytogenetic abnormalities in ALL include t 
(9;22), t (4 ;11) and q21, a count >1000/cumm on peripheral blood after 7 
days of prednisolone and one dose of intrathecal methotrexate and minimal 
residual disease>1%[13,64] 
 
TREATMENT: The average duration of treatment is two to two and a half 
years. The protocol used for treatment of ALL in India is MCP-841 
INDUCTIONS-1 (month 1 and month 3) 
L asparginase  6000 units/M2 alternate days 
Vincristine 1.4mg/M2 Once a week-5 doses  
Daunomycin 30mg/M2 days 8,15,28 
Prednisolone  40mg/M2 days 1 to 28 
I.T. Methotrexate  12mg/M2 days 1,8,15,22,28 
INDUCTION-2 (month 2) 
Cyclophosphamide 750mg/m2 days 1,15 
6-Mercaptopurine  75mg/m2 days 1 to 7, 15 to 22 
I.T  Methotrexate 12mg/m2 days 1,8,15,22 
Cranial radiotherapy 1200cGy days 5 to 15 
CONSOLIDATION (month 4) 
 
Vincristine  1.4mg/m2 days 1, 15 
Cyclophosphamide  750mg/m2 days 1 
Daunomycin 30mg/m2 days 15 
Cytarabine 100mg/m2 days 1,2,3 & 15,16,17 
6-Mercaptopurine  75mg/m2 days 1 to 8 & 15 to 22 
MAINTENANCE: (one in three months x 6 cycles) 
L asparginase  6000 units/M2 days 1,3,5,7 
Vincristine 1.4mg/M2 days 1 
Daunomycin 30mg/M2 days 1 
Prednisolone  40mg/M2 days 1 to 7 
6-Mercaptopurine 75mg/M2 days 15-90 (5 
days/week) 
Methotrexate 15mg/m2 days 15,22,29,….90 
once a week 
 
RELAPSE: 
25% of children with ALL relapsed during or after completing 
chemotherapy. The main sites of relapse are bone marrow, CNS, and the 
testes. Features of relapse are a morphological shift from small L1 blasts to 
larger pleomorphic L2 to L3 blasts, additional changes in cytogenetics 
occurs in 10% of cases [43] 
Treatment after relapse: Must be more aggressive to overcome the problems 
of drug resistance. After entering into second remission bone marrow 
transplantation offers chances of cure 
OUTCOME:   
The five year survival rates of the patients with ALL in reputed cancer 
institutes of India Vary from 45-55% [37,45].but the survival rate of cases in 
developed countries is about 80-85% [25] 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               REVIEW LITERATURE 
 
REPORTING IN INDIA: 
 
Population based data on the incidence of leukemia and other cancers 
in the developing countries are neither consistently available nor very 
reliable due to under registration and absence of organized registry .therefore 
hospital statistics in the developing countries provide the only available 
window to observe  the disease pattern in the community [14,17] 
 
EPIDEMIOLOGY: 
 
Acute lymphoblastic leukemia is the common type of all leukemias of 
about 62.5%o 75% [1,9,18] Age: the most common age group of ALL at 
presentation was 2-6 Years [18] with a peak Around 3-4 years.[3,20] This  
peak is mainly due to the predominance of pre B ALL cases in this age 
group. 
Sex: Incidence of ALL is higher in boys than in girls. Male: female ratio 
1.3:1[1,3,18] 
Etiology: various studies have not been able to conclusively prove any 
definite etiological risk factor for leukemia [19,20]. Down syndrome is the 
most common syndrome associated with 15 fold increase in risk of leukemia 
in first decade [3] 
CLINICAL FEATURES: 
 
Fever is seen in 100% of case of leukemia at the time of Presentation 
[1] In Indian studies about 56% of ALL present with fever as the main 
complaint [16,18]. Bleeding is seen in 30-40% of the leukemias at the time 
of presentation [1,9]. Pallor is seen in 100% of cases in both Indian and 
western studies. Testicular involvement at the time of diagnosis is 25%of 
cases and in 15% of cases who completed the treatment [42,44,47].But it can 
vary from 1-40% [64] 
  
Hepatosplenomegaly was seen in 68% of cases [10] in western 
literature. But in Indian literature it is about 87% [45].western studies state 
that lymphadenopathy is present in 50% [9,10] of cases. But Indian studies 
quote from 76%-85% [15,18,45]. Bone and joint pain were in 28%.  In 
Manipur study it is about 46.7%.Bilateral parotid swelling with massive 
hepatosplenomegaly is associated with poor prognosis [49] 
    
CNS COMPLICATIONS DURING LEUKEMIA:      
 
           This occur either due to the disease per se or of the side effects of 
therapy. CNS Involvement is reported to occur more in AML than ALL-the 
figures being 5%[10] for ALL and 5-15% for AML[29].seizures have been 
reported in 8-13% of the patients [29]. The most common cranial nerves 
involved due to leukemic infiltration are 2, 6, 7. Ophthalmic complications 
are seen in 9% of the children. Thrombosis and hemorrhage occurs in 1-2% 
of children. The majority of such complications occur in the third and fourth 
weeks of induction [29].According to Singh et al the 7th cranial nerve was 
the most common involved. The Revised criteria for CNS involvement at 
diagnosis, as quoted by Mastrangelo R [66] is as follows - 
  CNS-1 - one blast cell  
  CNS-2 - <5 WBC/micro litre with blasts cells 
 
             CNS-3 -> 5 WBC/micro litre with blasts or Cranial nerve 
involvement 
 
INFANTILE LEUKEMIA:  
 
Leukemia in infancy constitutes 3-5% of children with leukemia. 
Infantile leukemia has special biologic characteristics [9]. Western literature 
quotes that AML of the M4 or M5 type is more common in infantile 
leukemia with a relative female preponderance [9,10].congenital leukemia 
was diagnosed  only in 2 of the 115 cases reported by Reaman et al most of 
them were of AML type [30].However in a study conducted by somjee et al 
the department of medical oncology Tata Memorial hospital Mumbai, on 
cases of infantile leukemia, it was found that ALL-L1 was more common. 
With a relative male preponderance was reported [31] these patients had 
significant organomegaly, hyperleucocytosis and hepato-splenomagaly. 
LAB PARAMETERS: 
 
Despite the advent of modern ancillary techniques, morphologic 
examination and cytochemical staining of well-prepared air-dried peripheral 
blood smears and bone marrow smears are critical in the pathologic 
diagnosis and classification of acute leukemias. Hemoglobin is less than 
10mg/dl, the percentage varying from 80-96% in all the studies for ALL 
[1,18]. The total count is more than 50000 at the time of presentation in 17-
25% of the cases of ALL [10,11,18].  The total count more than >50,000 is a 
poor prognostic factor for ALL .In Manipur study[18] this was between 36-
46%.15 % of patients present with marked hyper leukocytosis. One third of 
patients present with platelet count less than 25000 x 106/litre33 and less than 
50,000 in 50% of cases Peripheral blasts may not be observed in 25-30% of 
the cases [26]. But in a Indian study [18] it is about 18.7%.  
 
MORPHOLOGIC CLASSIFICATION: 
           
According to Singh et al [18] L1 constituted 63.3% of the cases and L2 
36.7%. Other reviews quote L1 being about 80-85% L2 about 15% and L3 
1-2% [1,9;16] L1& L2 morphological types bear no relationship to 
immunological type or other prognostic factors. 
 Loffler H et al had noted that the identification of the L3 variant is of 
major importance. According to studies there is a high but not universal 
correlation of the L3 phenotype as defined by morphology with the 
immunologically defined B-ALL with surface expression of 
immunoglobulins [67]. 
            The prognostic significance of being able to distinguish between L1 
& L2 morphologic subtypes has never been fully proven. Findings with 
established prognostic significance, such as favourable and unfavourable 
cytogenetic alterations occur in both L1 & L2 .Similarly immuno phenotypes 
tht may be of prognostic significance do not correlate well with L1 & L2 
morphology.  
 IMMUNOPHENOTYPING 
 
The development of monoclonal antibody against cell surface markers 
of blood cells and their conjugation with certain flurochromes markedly 
contributed to the application of flow cytometry in the study of normal 
haematopoiesis.  
Commitment to B cell differentiation is indicated by the appearance of 
CD19 & CD10.Typical phenotype of peripheral B lymphocyte is CD19+, 
CD20+, CD21+ and CD22+.Majority of blood T lymphocytes are CD2+, 
CD3+ and CD7+ and express either CD4 or CD8. 
CD33 is the earliest marker for myeloid differentiation. Immature 
myeloid cells become CD13+ followed by appearance of CD15 and CD11b. 
in contrast monocytes are strongly CD33+ and weakly CD15 and CD4 
positive. 
Expressions of myeloid antigen marker are slightly more frequent in 
B-lineage ALL than in T-lineage ALL but have no prognostic value. 
        T cell ALL are subclassified into different stages corresponding to 
normal thymocyte development , the early subtype is negative for surface 
CD3  and is either double positive or double negative for CD4 and CD8 , the 
later subtype is surface CD3+and positive for CD4 or CD8 and not both. 
Recent studies do not find any prognostic differences in this sub 
classification of T cell ALL. 
          Lymphoblast lymphomas and ALL have more similarities than 
differences in pathology, immunophenotype, and genotypes and hence they 
have been regarded as process falling within the spectrum of a single disease 
entity. ALL and lymphoblast lymphomas are grouped under the category 
labeled lymphoblastic leukemia / lymphoma in the Revised European and 
American Classification of Lymphoid Neoplasm’s (REAL) and in the WHO 
Classification Scheme 
 The WHO classification does not group the ALL together, but 
separates them under three broader categories of lymphoid disease: 
1. Precursor B cell  
2. Precursor T cell 
3. Mature B cell neoplasms  
Bucheri V etal   had proposed a scoring system for a diagnosis of 
biphenotypic leukemia [68] 
Points B cell T cell Myeloid 
2 CD79a ,CD 
22 
cytoplasmic IgM
CD3 MPO 
1 CD 19 
,CD10 
CD2 CD5 CD33 CD13 
0.5 TdT TdT ,CD7 CD14 ,CD15, 
CD11c,CD11b 
 
Biphenotypic acute leukemia is established when score from two 
separate lineages score than 2. Recent studies include CD117 as a highly 
specific myeloid marker equivalent to 2 points and T cell receptor a highly 
specific T cell marker with 2 points 
CYTOGENETIC ABNORMALITIES: 
        It is now possible to demonstrate abnormalities in chromosome number 
or structure in over 90% of the cases of ALL[1] however even in the best of 
labs successful karyotyping are obtained only in 30-50% of the cases 
analyzed[33,34,35] 
      Several mechanisms contribute to tumor formation [34] 
1. Whole chromosome duplications-most frequent abnormality. This 
is seen in approximately 40% of cases. the most common whole 
chromosome duplications included X, 4,6,10,21 
2. Whole or partial chromosome deletion:  
3. Translocations :  result in the creation of either a tumor specific 
chimeric protein as a result of gene fusion leading to 
transcriptional dysregulation of the involved gene 
In a study conducted by Petkovic et al [36] on 55 children with ALL, 
they detected abnormalities in  63.6% of the cases. All children less than six 
months, 57.8% in the age group 1-10 years and 85.7% in the age group more 
than 10 years had aberrations. Common abnormalities detected were : 
hyperdiploidy more than 50, del 6and t[1,19]. In an analysis of 94 bone 
marrow karyotypes analysis of children with acute leukemia by Heimetal 
68% of All had chromosome abnormalities [38]. In ALL the most common 
abnormality was hyperdiploidy[49%] followed by deletion if 6q in 10.2% of 
the cases and re-arrangements of 12p in 6.4% only 0.7of hyperdiploidy 
where as 23.4%of cytogenetically and 30% of those with other structural 
abnormalities relapsed  
PROGNOSTIC FACTORS & RISK ASSESSMENT: 
ALL: 
Favourable risk factors include female sex, age 1 to 9 years, WBC 
count less than 50,000 cells per cumm, LI morphology, and hyperdiploidy. 
Adverse factors include: male sex, age less than 1 year and more than 
9 years, count more than 50,000 cells per cumm, L3 morphology, CNS 
disease, mediastinal mass, hypoploidy, Philadelphia chromosome and t 
(4;11), blast on day 7 or 14 after start of therapy. Advanced age and high 
WBC count at the time of diagnosis have a significantly adverse prognosis. 
Unfavorable cytogenetic abnormalities in ALL include t (9;22), t (4 ;11) and 
q21. A count >1000/cumm on peripheral blood after 7 days of prednisolone 
and one dose of intrathecal methotrexate and minimal residual disease>1% 
RISK ASSESSMENT 
IAP NATIONAL GUIDE LINES: [3] 
  High risk: 
1. Age less than 1year and more than 10   
2. CNS or testicular disease at presentation 
3. WBC count at presentation > 50000/cumm 
4. T-lineage ALL, pre-preALL  
5. philadelphia positive ALL 
Non high risk: 
 1. Age between 1 to 10 years 
 2. No CNS or testicular disease at presentation 
 3. WBC count <50000/cumm 
 4. CALLA positive ALL 
NATIONAL CANCER INSTITUTE’S RISK CLASSIFICATION:  
[B precursor ALL][62] 
 Standard 
  1. WBC count <50000/ul 2.age 1.00-9.99years 
High risk: 
  1. WBC count >50000   2.age <10 years 
POG RISK CLASSIFICATION: [55] 
Low risk:  
NCI consensus age and WBC criteria  
Absence of adverse translocations,  
Absence of CNS disease and testicular disease,  
The presence of either the TEL-AML1 translocation or trisomy of      
chromosomes 4 and 10.  
 High-risk group:  
Absence of favorable translocations 
Presence of CNS or testicular leukemia,  
The presence of MLL gene rearrangement,  
Unfavorable age and WBC count 
Very high-risk: 
  Presence of the t(9;22) 
 
  M3 marrow on day 29 or M2 or M3 marrow on day 43,  
 
Hypodiploidy (DNA index <0.95).[122]  
 
 
 
 
 
BFM: 
 
STANDARD RISK: 
 
Prednisone good responders (those with absolute blast count 
<1000/μL at the end of the prophase) 
 
HIGH RISK: 
 
Patients with an absolute blast count of 1000/μL or greater at the end 
of a 7-day 
 
 1. Prednisone prophase (prednisone poor responders)  
 
   2. All patients with the t (9;22) ,t[4,11] 
  
 3. MRD>10-3 
 
MODERATE RISK  
1. All patients with T-cell phenotype, mediastinal mass, or CNS 
involvement were considered 
2. MRD <10>-3 
 
PROGNOSTIC GROUPS UNDER CLINICAL EVALUATION  
 
CLASSIFICATION SYSTEM FOR THE COG. [55] 
  
Based on this analysis, patients with precursor B-cell ALL are initially 
assigned to a standard-risk or high-risk group based on age and initial WBC 
count (aged 1–9.99 years, and <50,000 WBC/µL is considered standard 
risk). All children with T-cell phenotype are considered high risk regardless 
of age and initial WBC count. Early treatment response (assessed by day 7 
or day 14 marrow morphology and end-induction MRD assessment) and 
cytogenetics are subsequently used to modify initial risk-group 
classification. NCI standard-risk patients with rapid morphologic response 
(day 14 M1 marrow) and MRD less than 0.1% and an M1 marrow on day 29 
are assigned to one of two groups based on cytogenetics. Patients with either 
t(12;21) or trisomies of chromosomes 4, 10, and 17 are considered "standard 
risk-low while patients with neither of these two cytogenetics abnormalities 
are considered standard risk-average." Standard-risk patients with either 
slow morphologic response(either day 7 or day 14 M1 marrow) and/or MRD 
more than 0.1% on day 29 are assigned to a third group (standard risk-high) 
and receive a more intensive post induction treatment. High-risk patients 
with precursor B-cell ALL are divided into rapid-responder (rapid 
morphologic response and low MRD) or slow-responder groups. Patients are 
classified as very high risk if they have any of the following features 
(regardless of initial risk group): t(9;22), hypodiploidy less than 44 
chromosomes, MLL translocation with a slow early morphologic response, 
M3 marrow on day 29 or M2 marrow and/or MRD greater than 1% at days 
29 and 43.  
THE DANA-FARBER CANCER INSTITUTE (DFCI) ALL  
 
CONSORTIUM is also testing a new risk classification system for 
patients with precursor B-cell ALL. All patients are initially classified as 
either standard risk or high risk based upon age, presenting leukocyte count 
and the presence or absence of CNS disease. At the completion of a five-
drug remission induction regimen (4 weeks from diagnosis), the level of 
MRD is determined. Patients with high MRD (≥0.1%) are classified as very 
high risk and receive a more intensive post remission consolidation. Patients 
with low MRD (<0.1%) continue to receive treatment based on their initial 
risk-group classification. The goal of this new classification schema is to 
determine whether intensification of therapy will improve the outcome of 
patients with high MRD at the end of remission induction. Patients with T-
cell ALL are treated as high risk, regardless of MRD status. All patients with 
MLL translocations or hypodiploidy (<45 chromosomes) are classified as 
very high risk regardless of MRD status or phenotype. Patients with the 
Philadelphia chromosome are treated as high risk, but receive an allogeneic 
stem cell transplant in first remission. 
At ST. JUDE CHILDREN'S RESEARCH HOSPITAL, risk 
classification is based mainly on MRD level (assessed by flow cytometry) 
after 6 weeks of remission induction therapy as follows: low risk (<0.01%), 
standard risk (0.01% to <1%),and  high risk (≥1%).  
T-cell Acute Lymphoblastic Leukemia  
Historically, patients with T-cell acute lymphoblastic leukemia (ALL) 
have had a worse prognosis than children with precursor B-cell ALL. With 
current treatment regimens, outcomes for children with T-cell ALL are now 
approaching those achieved for children with precursor B-cell ALL. For 
example, the 5-year event-free survival (EFS) for children with T-cell ALL 
treated on the Dana Farber Cancer Institute (DFCI) Consortium ALL 
protocols was 75% compared with 84% for children with precursor B cell 
ALL Protocols of the former Pediatric Oncology Group (POG) treated 
children with T-Cell ALL distinctly from children with B-lineage ALL. The 
POG-9404 protocol for patients with T-cell ALL was designed to evaluate 
the role of high-dose methotrexate and the role of the cardio protectant 
dexrazoxane. The multi agent chemotherapy backbone for this protocol was 
based on the DFCI 87-001 regimen. Results of an interim analysis of the 
POG protocol led investigators to conclude that the addition of high-dose 
methotrexate to the DFCI-based chemotherapy regimen results in 
significantly improved EFS, due in large measure to a decrease in the rate of 
central nervous system (CNS) relapse. This POG study was the first clinical 
trial to provide convincing evidence that high-dose methotrexate can 
improve outcome for children with T-cell ALL. High-dose asparaginase and 
doxorubicin were also important components of this regimen. 
Infants with Acute Lymphoblastic Leukemia              
Infant ALL is uncommon, representing approximately 2% to 4% of 
cases of childhood ALL [31]. Because of their distinctive biological 
characteristics and their high risk for leukemia recurrence, infants with ALL 
are treated on protocols specifically designed for this patient population. 
Despite intensification of therapy, long-term EFS rates from recent trials 
remain below 50%, and for those infants with MLL gene rearrangement the 
EFS rates continue to be in the 30% to 40% range. Common therapeutic 
themes of the intensive chemotherapy regimens used to treat infants with 
ALL are the inclusion of post induction intensification courses with high 
doses of cytarabine and methotrexate. 
RELAPSE: 
25% of children with ALL relapse after treatment.[1,16]. The main 
sites of treatment are bone marrow, CNS, and the testes. Features of relapse 
are a morphological shift from small L1 blasts to larger pleomorphic L2 to 
L3 blasts, additional changes in cytogenetics occurs in 10% of cases [43] 
primary relapse has also been reported in anterior segment of the eye. 
according to VP Choudry et al the incidence of relapse is very high in the 
Indian scenario being about 30%[41].The reasons are 60% of the Indian 
children are high risk at the time of diagnosis, higher prevalence of T cell 
leukemia, less intensive chemotherapy and poor compliance. Relapses are 
classified as early if it occurs within the first 18 months, intermediate if it 
occurs between 18-36 months and late if it occurs after 36 months [24]. 
Most relapses in all occur in the first 5 years of diagnosis. Combined 
relapses [bone marrow and extra medullary] often occur later than isolated 
bone marrow. While isolated CNS relapse tends to occur within 3 years of 
diagnosis, testicular relapse after the treatment has been stopped. The 
survival of children with bone marrow and CNS relapse reported to be less 
than 20%.[43] 
Testicular relapse: 
According to Arya et al it is seen in 3% of cases in the UKALL study 
12% of children developed testicular relapse over 15 years from 1972to 
1987[47].children with early testicular relapse or during therapy had a worse 
prognosis. Incidence of biopsy proven occult testicular leukemia is estimated 
to be around 25% and that of overt disease is about 16% during the course of 
the therapy [44].The percentage increases after the full course of therapy is 
completed. The lymphoblasts in the interstitium of the testis somehow [40] 
escape the onslaught of the drugs due to the presence of blood testis barrier. 
Event free survival in the second remission is poor .Favorable factors 
include Isolated testicular relapse, combined bone marrow and extra 
medullary relapse, duration of Clinical remission more than 24 months, 
initial age at diagnosis between 2-6 years and WBC count below 10000 at 
the time of relapse [43,44].older age group, T cell disease and bone marrow 
relapse are poor prognostic factors. Studies conducted at Sweden reveals that 
the most important prognostic factor was the duration of the first complete 
remission [43,44]. 
SURVIVAL AND OUTCOME: 
Since the introduction of total therapy as first described by Pinkel [23] 
in 1971  the prognosis in ALL has improved from less than 5% survival 
before 1965 to 25%-50% during the 70s to 70% during the 80s and 80% for 
children in the 1990s.[1] 
It is estimated that only one out of ten children with acute leukemia 
receive any kind of treatment in these less privileged countries. Hence even 
though 70% of childhood ALL is currently curable, it is not 70% Curable 
World wide, since 90% of the world children do not have access to curative 
treatment [15]. 
         According to LS Arya et al the survival rate at All India institute of 
medical sciences is 51% [16]. Five years survival for ALL patients in USA 
is 87.8% and 10 year survival is 83.8% [25]. A study from vellore [27] at 
2003 five year overall gives survival rate is 59.8%, event free survival rate is 
56% and disease free survival is 53.9%. In another study from china 
conducted at 2006 the 5 years EFS is about 51.50%[12].In the  study from 
Chennai [59] the EFS calculated for 4 years is 18%, 3 years 31% 2 years is 
41%. Many other Indian literature reviews reveals the same   
         Reasons attributed to decreased survival in India compared to the 
developed countries are 
1. The financial burden of treatment 
2. Poor compliance and large no of drop outs 
3. Lack of availability of good supportive care and poor tolerance 
to chemotherapy by the malnourished patients 
4. High incidence of infections 
5. High incidence of T cell leukemia in Indian population and 
cytogenetic abnormalities that predict poor outcome  are more 
common 
 
 
 
 
 AIM OF THE STUDY 
 
 
To study the outcome of children with Acute Lymphoblastic 
Leukemia admitted at Government Rajaji Hospital from the year August 
2003 to July 2008, a total period of five years.  
OBJECTIVES:  
PRIMARY:   
  To know the outcome of Acute Lymphoblastic Leukemia patients   
diagnosed and treated in GRH  
SECONDARY: 
1. To analyze the risk factors causing relapse and poor outcome in 
treated patients 
2. To assign a risk classification with a available clinical and 
laboratory datas 
 
 
                                            
 
 
 
 
 
 
 
 
 
DESIGN AND SETTINGS 
 
 STUDY DESIGN:  
  Prospective   and retrospective study.  
  STUDY PERIOD:    
Retrospective study from august 2003 to November 2006. 
Prospective study from December 2006 to July 2008 
STUDY PLACE: 
  Hospital based study conducted in the hematology ward, Institute of 
child health and research centre, Government Rajaji Hospital, Madurai, 
Tamilnadu, India.  
STUDY POPULATION:  
  All confirmed cases of Acute Lymphoblastic Leukemia who were 
enrolled and on treatment during the study period were the subjects of the 
study. 
SAMPLE SIZE:  92 patients                    
 INCLUSION CRITERIA: 
All cases of Acute Lymphoblastic Leukemia diagnosed and treated in 
hemato-oncology ward 
EXCLUSION CRITERIA:  nil 
MATERIAL AND METHODS 
Case Selection: 
 All confirmed cases of Acute Lymphoblastic Leukemia who were 
enrolled at the start of the study and who were diagnosed earlier and on 
treatment during the study period were the subjects of the study. The project 
was approved by hospital ethics committee and due consent was obtained 
from the patient’s parents before the start of the study. 
 A thorough history was taken and followed with a detailed physical 
examination in each case. The case sheets of patients diagnosed with 
leukemia and undergoing treatment during the same period were collected 
from the Medical Record Department of Government Rajaji Hospital, 
Madurai and analyzed. Registers in Hemato oncology ward and patient’s 
records were also analyzed. Data collected were entered in a structured 
proforma. 
 The following investigations were performed for each case. 
Hemoglobin, total count, differential count, platelet count, serum uric acid, 
base line liver and renal function test, chest x-ray, Electro cardiogram, Echo 
cardiogram, Ultra Sonogram abdomen, CSF analysis for malignant cells. 
Cytochemical studies, immunephenotyping were done for selected cases. 
Possible microbiological investigation and imaging studies were performed 
in   appropriate cases.  
Treatment: 
 All patients diagnosed were treated with the common protocol MCP 
841 without any risk categorization considering all patients at high risk.  
 Duration for treatment was for 22 months. All the cases who were on 
and completed chemotherapy were followed up regularly.  
Outcome of ALL patients is analyzed as 
1. Alive without relapse  
  2. Alive with relapse 
3. Death before first remission  
4. Death after remission and relapse 
 Correlation between outcome and individual prognostic factor was 
made. 
With the available clinico pathological date a risk scoring was done 
and correlated with the outcome. 
Prognostic factors: 
              Age, sex, WBC count at the time presentation, Hb, platelet count, 
liver size, spleen size, lymphadenopathy, presence or absence of mediastinal 
lymphadenopathy, FAB   morphology, no of blasts in bone marrow and the 
rapidity of response to therapy   were analyzed with the outcome. 
RISK SCORING 
S. 
No. 
Prognostic factor Good 
prognosis 
Poor 
prognosis 
Very poor 
prognosis 
1. Age >2, <10[0] 1-2, >10[1] <1[2] 
2. Sex Female[0] Male[1]  
3. WBC count <10,000[0] 10,000 -
50,000[1] 
>50,000[2] 
4. Platelet count >1,00,000[0] 50,000-
1,00,000[1]
< 50,000[2] 
5. HB >8[0] 5 – 8[1] < 5[2] 
6. FAB morphology  LI[0] L2 or 
L3[1] 
 
7. No of bone marrow 
blasts 
<50[0] 50 – 90[1] >90[2] 
8. Liver size [more 
than the span of 
their age] 
Nil[0] < 5 cms >5cms[2] 
9. spleen       size Nil[0] <5cms[1] >5cms[2] 
10. Lymph node size Nil[0] < 3 cms[1] > 3cms[2] 
11 Mediastinal 
lymphadenopathy 
Absent[0] Present[1]  
12 Disappearance  of 
blasts in  PS 
With in 7 
days[0] 
7-14 
days[1] 
>14 days[2] 
 
RISK STRATIFICATION: A score of 0’ was allotted for a prognostic 
factor with good prognosis; a score of 1’ was allotted to the factor with poor 
prognosis and a score of 2 for with very poor prognosis                              : 
If the score is below 8    low risk 
If the score is between 8-14  high risk 
If the score is 15 and more than 15 very high risk 
After allotting different risk groups, the correlation between these 
groups and the outcome was drawn.       
Sample collection and processing: 
On suspicion of leukemia, bone marrow was aspirated from the iliac 
crest of patients. Slides were prepared and then dried for cytochemical 
staining with in 48 hours. 
 5ml of heparinized venous blood sample were taken for 
immunophenotyping analysis. 
Periodic Acid Schiff staining: 
Procedure: The air dried blood films are fixed for one minute at room 
temperature in formalin ethanol fixative solution and then rinsed for one 
minute in running tap water. The slides are then immersed in periodic Acid 
Schiff solution followed by rinsing in several changes of distilled water. 
This is followed by immersion in Schiff reagent and then washing in running 
tap water for five minutes. The slides are then counter stained in 
hematoxylin solution. The slides were then examined under the microcopy 
for PAS positivity in block pattern 
Data Analysis 
 Computer analysis of statistical data was done. Using the 
epidemiological information package [2002] developed by World Health 
organization. P value was calculated using chi-square test. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
Total no of cases registered are 92.  33 cases are alive and 51 cases died.6 
cases were absconded with case sheet. One case was referred to Chennai and 
lost follow up. One case was not on follow up after 2nd maintenance. Age, 
sex and outcome details are available for 92 patients. Complete clinical and 
laboratory details are available for 73 patients only. The details of 11 
patients could not be traced. 
AGE: 51 cases were in the age between 2-6 years [54.52%]. 12cases were 
>10years of age. 3 cases were in the age group of 1-2 years. Infantile 
leukemia is about 2.2%. 
SEX: 52cases are males and 40 cases are females. Male: female ratio is 1.3 
 
PRESENTING SYMPTOMS: 
 
        Out of 73 cases 71 [96.6%] cases presented with fever. Neck swelling 
was the presenting complaint in 40 cases [54.7%] and abdominal distension 
in 52 cases [53.4%]. 30cases were [42.8%] presented with bleeding 
manifestations at the time of diagnosis. Bone pain was complained in 20 
cases [27.3%].2cases   presented with joint pain only. Testicular enlargement 
was present at the time diagnosis in one case [1.3%]. One case presented 
with loss of vision and another case with paraplegia 
 
PHYSICAL EXAMINATION: 
 
  Pallor  was noticed in 70 cases [95.8%] .Significant lymphadenopathy  
was present in 62 cases [84.9%], and bleeding manifestations in 32 cases 
[43.8%].Bony tenderness noticed in 30 cases [42.8%].Bilateral testicular  
enlargement noted in one case [1.3%]. Bilateral parotid enlargement was 
present in 16 cases [21.9%]. Hepatomegaly was present in all cases. Liver 
was palpable more than 5 cm in 60% Cases. Splenomegaly was present in 70 
cases [95.8%]. 3 cases were without splenomegaly. More than half of them 
had a spleen size of more than 5 cm .one case presented with bilateral Sub 
retinal hemorrhage 
LABORATORY FINDINGS: 
Hemoglobin : This was less than 5gms/ dl in 34 case [46.5%] and less 
than 8gms/dl  in 84.9% cases.11 cases were with a hemoglobin between 8-
11.WBC count: Majority of ALL [ 52%] had WBC  counts between 10,000-
50000/cumm , 24.6% with <10,000 and 23.2% with a count of >50000 at the 
time of presentation. Platelet count: nearly 65% cases presented with a 
platelet count of <50,000 at the time of Diagnosis .Only nine cases [12.3% ] 
had the count of more than one lakh. The remaining 16 cases [21.9%] had 
the counts between 50,000-100,000. 
 
  
PERIPHERAL SMEAR: 
No of blasts No of cases Percentage 
0 9 12.3% 
<50 11 15% 
50-90 38 52% 
>90 15 20.5% 
 
BONE MARROW EXAMINATION: 
 
No of blasts No of cases Percentage 
>90 21 28.7% 
50-90 47 64.38% 
<50 5 6.8% 
 
FAB morphology: L1 morphology was in 40 cases [54.7%] and L2 in 
33 cases.  
 
IMMUNO PHENOTYPING: done for nine cases only. Precursor B–ALL 
was typed in 5 cases and mature B cell ALL in one case.3 cases [33.3%] had  
 ECTHYMA GANGRENOSUM WHICH YIELDED  
             PEUDOMONAS ON CULTURE 
 
 
 
 DIFFUSE LEUKEMIC INFILTRATION IN THE  
                      BRAIN PARENCHYMA 
 
 
 
 
T cell ALL 2 cases of T cell ALL relapsed and died. 1 case is on treatment. 2 
cases of B cell ALL died one had relapsed. 3 cases on chemotherapy. 
MEDIASTINAL LYMPHADENOPATHY: 
11 cases were presented with [15%] mediastinal lymphadenopathy at 
the time of Presentation. Immunophenotyping was not done for these cases 
RENAL ENLARGEMENT: 
Bilateral renal enlargement was present in 5 cases and unilateral renal 
swelling in one case [9.5%].One case with renal failure and died before 
starting on chemotherapy. Only one case completed chemotherapy and is 
alive now.  Remaining four cases were relapsed and died.  
CNS INVOLVEMENT: 
Two cases were presented with CNS involvement at the time of 
presentation [4.1%].One case with multiple parenchymal infiltrations in 
brain and died before starting Chemotherapy. Another case was presented 
with paraplegia, spinal infiltration and renal involvement along with CNS 
leukemia and died before remission .The third case developed sub retinal 
hemorrhage along with CNS involvement during chemotherapy. 
 
 
 
  
           SUSPECTED CASE  OF PULMONARY 
ASPERGILLOSIS  AND    DIED DUE TO MASSIVE   
                           HEMOPTYSIS 
 
 
 
 PNEUMO CYSTOSIS CARINII [JIROVECI]  
                          PNEUMONIA 
  
 
 
OPHTHALMOLOGY:  
One case presented with sub retinal hemorrhage and one case 
developed the same during chemotherapy. One case developed exposure 
keratitis due to 7th nerve palsy and resolved. One case developed corneal 
opacity after an infectious episode in the eye.  
SKELETAL: 
 
One case was presented with leukemic infiltrate in vertebrae. Another 
Case developed tuberculosis of spine after therapy. Four cases had fracture 
during therapy. 
 
PULMONARY: 
 
Five cases had radio logically proved lobar consolidation. One case   
was suspected of pulmonary aspergillosis and died due to massive 
haemoptysis during induction. One case developed pneumocytosis carinii 
pneumonia during maintenance and recovered. 
RAPIDITY OR RESPONSE: 
29 cases [49.6%] showed absence of blasts in the peripheral smear 
after seven days of chemotherapy, 20 cases [33.8%] after 7- 14 days of 
chemotherapy and 14.5% of cases after 14-28 days of chemotherapy. Two 
cases had blasts even after one month of therapy 
 
 
RESULTS ON OUTCOME 
 
Total no of cases registered  : 92 
 
Total no of   alive cases   : 33 
 
Total no of deaths    :         51 
 
Lost follow up    : 8 
 
       1. Absconded    : 7 
 
       2. Referred to higher centre : 1 
  
Total no of relapse cases   : 28    
 Alive - 7 cases  
Death -  21 cases 
 
YEARWISE   DISTRIBUTION   OF CASES 
 
Year   [from 
July] 
Total no 
cases alive Death 
Lost 
follow up Relapse 
2003 - 2004 30 6 22 2 13 
2004 - 2005 21 6 12 3 8 
2005 - 2006 13 7 5 1 4 
2006 - 2007 14 7 5 2 3 
2007 - 2008 14 7 7 -- -- 
Total 92 33 51 8 28 
OUTCOME OF    LIVE   CASES: 
 
Total no of cases 33 
Completed chemotherapy 14 
On chemotherapy 19 
 
Completed chemotherapy: 
 
Completed chemotherapy and in remission   : 14 
 
Completed chemotherapy but relapsed   : 3 
  and on chemotherapy 
One case had relapse in the sclera after 6 months of therapy. Another 
case had testicular relapse followed with bone marrow relapse after 9 
months of therapy. Third case had isolated testicular relapse   after one year 
of therapy. 
EVENT FREE SURVIVAL: Event free survival is calculated for 
patients who completed chemotherapy and in remission. Duration was 
calculated from the starting day of chemotherapy to July 2008 
Survival in years No of cases Percentage 
4 years 5 5.4% 
3 years 10 10.8% 
2 years 14 15.2% 
ON CHEMOTHERAPY:    Total no cases on chemotherapy: 19 
 
S. No On chemotherapy Total no cases 
1. a. Completed chemotherapy but relapsed and in chemotherapy 3 
 On 1st  Maintenance 1 
 On 2nd Maintenance 1 
 On Induction 1 
2. b. Relapsed during chemotherapy 4 
 On 1st  maintenance 3 
 On  re induction 1 
3. C .Without relapse 12 
 On 5th maintenance 3 
 On 4th maintenance 1 
 On 3rd maintenance 2 
 2nd maintenance 2 
 On 1st maintenance 3 
 On consolidation 1 
 
Total no. cases  : 92 
 
Total no live cases  : 33 
 
Overall survival rate : 35.8% 
 
OUTCOME OF DEATH CASES: 
 
Total no cases  : 51 
 
Outcome is analyzed   in the three ways of death in these patients 
 
 
S. No. Death No. of 
cases 
Percentage 
1. Before starting chemotherapy 11 21.5% 
2. Before first  remission 19 37.2% 
3. After remission and relapse 21 41.1% 
 
 
YEARWISE DISTRIBUTION OF DEATH CASES: 
 
 
            
Year Before  
chemotherapy 
Before  first 
remission 
After  remission
[relapse] 
2004 3 8 12 
2005 3 3 7 
2006 2 3 - 
2007 1 2 2 
2008 2 3 - 
TOTAL 11 19 21 
 
 
 
 
CAUSE OF DEATH:  
 
  Death details were available for 40 patients only. In majority of 
the cases the cause of the death was bleeding [85%].Five cases [12.5%] died 
due to sepsis. One case died due to extensive leukemic infiltrate in the brain 
 
OUTCOME OF RELAPSE:   
 
 
Total 28 Percentage 
Alive 7 25% 
Death 21 75% 
 
Total no of cases registered : 92 
 
Total no of relapsed cases : 28        
  
Relapse rate   : 30.4% 
 
Most common site of relapse was bone marrow. Next to that was 
testicular relapse.22 cases were males. Most of the relapses were during 
maintenance period only. The outcome of the relapsed patients was death in 
more than two-third   of cases.                                              
 
 
 SITES OF RELAPSE 
 
Total 28 100% 
Bone marrow 21 75.2% 
Testicular 6 21.4% 
CNS 1 3.4% 
 
 CNS relapse case also had bone marrow relapse. Among six patients 
with testicular relapse two were with isolated testicular relapse and the 
remaining four with bone marrow relapse 
TIME OF RELAPSE:       
 
 
cycle alive death 
Re induction 1 - 
Maintenance-1 1 8 
Maintenance-2 0 9 
Maintenance-4 1 2 
Maintenance-6 1 2 
After completing chemotherapy 3 - 
 
 
 
 
CORRELATION   BETWEEN PROGNOSTIC FACTORS 
AND OUTCOME 
Complete details were present for 73 cases only. Correlation was made 
between the outcome and twelve prognostic factors for 73 patients. Score of 
0 was given to a factor with good prognosis, score of 1 for poor prognosis 
and a score of 2 for with very poor prognosis. 
AGE:  
 
 
Outcome 
 
 
Prognostic factor 
A AR D DR 
 
Total 73 
21 5 18 12 56 0 >2, <10 
37.5% 8.9% 32.1% 21.4% 100.0% 
5 1 5 4 15 1 1-2; >10 
33.3% 6.6% 33.3% 26.6% 100.0% 
  2  2 
AGE 
2 <1; 
  100.0%  100.0% 
                        
P value: 0.170 >0.05 is not significant [A-alive, AR-alive after 
relapse, D-death, D-death after relapse]  
There is no correlation between age and the outcome. Age is not a 
significant risk factor in predicting the outcome 
SEX: 
 Male –score 1 
 Female—score 0 
 
Outcome  
Prognostic factor A AR D DR 
Total 
73 
15 6 13 8 42 
1 Male 
35.7% 14.3% 31.0% 19.0% 100.0% 
11 - 12 8 31 
Sex 
0 Female 
35.5% - 38.7% 25.8% 100.0% 
 
P value: 0.245 >0.05% not significant  
 
There is no correlation between sex and the outcome. Sex is not a 
significant risk factor in   predicting the outcome. 
 
WBC COUNT: 
        WBC count <10,000/cumm  - 0 score 
   10,000-50,000/cumm - 1 score 
   >50,000/cumm  - 2 score 
 
 
OUTCOME 
Prognostic      factor 
A AR D DR 
Total 
73 
11 4 2 1 18 0  
<10,000 61.2 22.2% 11.1 5.6% 100.0% 
11 0 16 11 38 1 10,000-
50,000 46.8% 9.3% 31.2% 12.5% 100.0% 
4 2 7 4 17 
WBC 
COUNT 
2 >50,000 
23.5% 11.8% 41.2% 23.5 100.0% 
 
P value 0.001. < 05  is significant.  
 
There is a definite correlation between WBC count and the outcome 
as a prognostic factor 
 
 
 
 
 
 
 
 
 
         
WBC COUNT 
 
PLATELET COUNT: 
 
Platelet count: 
> 1,00,000  - 0 score 
50,000-1,00,000 - 1 score 
<50,000  - 2 score 
 
 
OUTCOME 
Prognostic factor 
A AR D DR 
Total 
73 
 
7  2  9 
0 
> 1 LAKH
77.8% 3 22.2%  100.0% 
10 2 2 2 16 
1 
50,000-1 
LAKH 62.5% 12.5% 12.5% 12.5% 100.0% 
9 4 21 14 48 
PLATELET 
2 
<50,000 
18.8% 8.3% 43.8% 29,2% 100.0% 
 
P value   0.0001   <0.05   is significant.  
There is definite   correlation between   platelet count and the outcome 
as a prognostic factor. 
 
 
HEMOGLOBIN: 
Hemoglobin:      >8gms/dl  - 0 score 
   5-8gms/dl    - 1 score 
   <5gms/dl  - 2 score 
 
outcome Prognostic factor 
A AR D DR 
Total 
73 
6 2 2 1 11 
0 
 
>8 54.5% 18.2% 18.2 9.1% 100.0% 
11 3 9 5 28 
1 5-8 
39.3% 10.7% 32.2% 17.9% 100.0% 
9 1 14 10 34 
HEMOGLOBIN 
2 <5 
35.6% 8.2% 34.2% 31.9% 100.0% 
 
 
P value 0.225. > 0.05 not significant  
 
There is no correlation between hemoglobin and the outcome. 
Hemoglobin is not a significant risk factor predicting the outcome 
 
 
 
 
MEDIASTINAL LYMPHADENOPATHY: 
 
   Absent - 0 score 
   Present - 1 score 
Outcome Prognostic factor 
 A AR D DR 
Total 
73 
30 5 11 16 62 
0 absent 48.1% 31% 17.7% 26% 100%
2 3 1 5 11 Mediastinal lymph adenopathy 
1 present 18.1% 27.2% 9.09% 45.4% 100%
 
P value   0.024   <0.05   is significant.  
 
 
There is a definite correlation between mediastinal lymphadenopathy  
and the outcome as a prognostic factor 
 
LYMPH NODE SIZE: 
No significant lymphadenopathy   - 0 score 
Size less than 3 cm                         - 1 score   
Size more than 3 cm                       - 2 score         
 
Outcome  
Prognostic factor A AR D DR 
 
Total 
73 
9 - - - 2 11 0 NIL 
81.8% - -- 18.2% 100.0%
10 4 12 6 32 1 <3 CM 
34.5% 13.8% 41.4% 10.3% 100.0%
5 2 12 11 30 
LYMPH 
NODE 
SIZE 
2 >3 CM 
17.9% 7.1% 42.9% 32.1% 100.0%
 
P value 0.001.   <0.05 is significant.  
 
There is a definite correlation between lymph node size and the 
outcome as a prognostic factor 
 
LIVER SIZE: 
 Score 0 - normal liver span for corresponding age 
  Score 1 - increased liver span for the age, <5 cm  
 Score 2 - increased liver span for the age, > 5cm 
 
 
outcome 
 Prognostic factor 
A AR D DR 
Total 
73 
- - - - - 
0 
 
NIL - - - - - 
16 4 7 2 29 
1 <5CM 
55.2% 13.8% 24.1% 6.9% 100.0% 
10 2 18 14 44 
LIVER 
SIZE 
2 >5CM 
22,7% 4.5% 40.1% 31.8% 100.0% 
 
 
  P value 0.004.  <0.05   is significant.  
 
There is definite correlation between liver size and the outcome as a 
prognostic factor 
 
 
SPLEEN SIZE: 
  No splenomegaly     - 0 score 
   Spleen palpable <5cm   - 1 score 
  Spleen palpable >5cm   - 2 score 
 
outcome 
 Prognostic factor 
A AR D DR 
Total 
73 
1 1 - 1 3 
0 
 
NIL 33.3% 33.3% - 33.3% 100.0% 
15 3 10 4 32 
1 <5CM 
46.8% 9.3% 31.2% 12.5% 100.0% 
8 1 17 12 38 
SPLEEN 
SIZE 
2 >5CM 
21.0% 2.6% 44.7% 31.5 100.0% 
 
P value    0.031   <0.05   is significant.  
 
There is a definite correlation between spleen size  and the outcome as 
a prognostic factor 
 
 
FAB CLASSIFICATION 
L1 morphology  - 0 score 
L2 morphology  - 1 score 
Outcome  
Prognostic factor A AR D DR 
Total 
73 
16 4 14 6 40 
0 L1 
40.0% 10.0% 35.0% 15.0% 100.0% 
10 2 11 10 33 
FAB 
1 L2 
30.3% 6.06% 33.3% 30.3% 100.0% 
 
P value is    0.245   >0.05    is not significant.  
 
There is no correlation between the FAB morphological classification 
and the outcome as a prognostic factor 
 
 
 
 
 
 
 
 
 
 
 
 
BONE MARROW BLASTS 
No of blasts if <50  - 0 score 
No of blasts if 50-89 - 1 score 
No of blasts > 90  - 2 score 
 
Outcome 
Prognostic factor 
A AR D DR 
Total 
73 
5    5 
0 
 
N<50 100    100.0% 
17 5 14 11 47 
1 
50-89 
36.2% 10.6% 29,8% 23.4% 100.0% 
4 1 11 5 21 
BONE 
MARROW 
BLAST 
2 
>90 
19% 4.8% 52.4% 23.8 100.0% 
 
 
P value is    0.020   <0.05    is significant.  
 
There is a definite correlation between the no of the bone marrow 
blasts and the outcome as a prognostic factor 
 
 
 
 
RAPIDITY OF RESPONSE: 
11 cases died before starting chemotherapy. So the rapidity of 
response was noted in 59 cases only. 
 
 
Outcome Prognostic factor 
A AR D DR 
Total 
59 
20 1 4 4 29 
0 
<7 
DAYS 69% 3.4% 13.8 13.8% 100.0% 
2 3 6 9 20 
1 
7-14 
DAYS 10% 15% 30% 45% 100.0% 
4 1 3 2 10 
DISAPPERAN
CE OF 
BLASTS IN 
PS 
2 
>14 
DAYS 40% 10% 30% 20 100.0% 
 
P value 0.007   < 0.05   is significant. There is a definite correlation 
between rapidity of response and the outcome as a prognostic factor  
There is a significant and definite correlation noted between initial 
white blood cell count, platelet count, mediastinal lymphadenopathy, lymph 
node size, liver size, spleen size, no of bone marrow blasts and rapidity of 
response with the future outcome and relapse. There is no correlation   
between age at the time of presentation, sex, hemoglobin and  FAB 
morphology and outcome 
  
 
RAPIDITY OF 
RESPONSE
 
 
RISK SCORING: After summing the all scores for prognostic factors 
 
 
 
OUTCOME 
  RISK SCORING 
A AR D DR 
Total 
73 
16 2 1 0 19 LOW 
RISK 
<8 
84,2% 10.5% 5.3% - 100.0%
9 3 23 13 48 HIGH 
RISK 
8-14 
18.8% 6.3% 47.9% 27.1% 100.0%
1 1 1 3 6 
RISK 
SCORING 
VERY 
HIGH 
RISK 
>15 
16.7 16.7% 16.7% 50% 100.0%
 
  P value 0.0001.  <0.05 is significant. There are 19 patients in low risk 
category. 18 patients are alive with only one death. There are 48 patients in 
high risk category.36 cases were died and only 12 cases are alive with 
relapse of three cases. There are 6 patients in very high risk category. 4 cases 
were died and only 2 cases are alive and with relapse of one case. There is a 
poorer outcome with patients of high and very high risk patients than 
with patients of lower risk.  
 
 
 
SCORING 
 
84.2
18.8
16.7
10.5
6.3
16.7
5.3
47.9
16.7
0
27.1
50
0
10
20
30
40
50
60
70
80
90
100
Low risk High risk very high risk
A AR D DR
Low risk cases showed good prognosis than high risk and very high risk 
cases. 
 
 
 
 
 
 
 DISCUSSION 
 
 
 
AGE:  
       
In accordance with literature the most common age group was 2-6 
Years [1,2,3]. Infantile leukemia was constituting about 2.2% of the total 
cases as compared to 3-5% in other reviews [9,10]   
 
SEX: 
      
There was a definite male preponderance in the study with male to 
female ratio of 1.35:1. It is comparable with western [1,9] as well as Indian 
literatures [18]. 
 
PRESENTING COMPLAINTS 
        
Fever was present in 95% of cases in this study.  It is a very common                             
Presentation in Indian studies than in western. Bleeding was present in 
43.8% of cases and is comparable with the other studies 
symptoms Present study Bangalore 
study [18] 
Other 
reviews[9,10] 
fever 95% 56.7% 61% 
bleeding 43.8% 30% 48% 
Bone pain 42.8% 46.7% 28% 
Pallor  95.8% 100% 100% 
Testicular 
involvement 
1.3% nil 25% 
CNS 
involvement 
4.1% 3.3% 5% 
 
Physical examination: 
 
Hepatomegaly and splenomegaly were noted in >90% of cases which 
is comparable with most of the Indian studies in contrast with many western 
studies [9,10]. Lymphadenopathy was present in >80% of cases. But from 
western statistics it is only about 50% 
Clinical feature Manipur 
study[18] 
Tata 
memorial[45]
AIIMS 
study[37] 
Other 
reviews[9,10] 
Present 
study 
hepatomegaly 100% 80% 95% 68% 100% 
splenomegaly 98% 78% 90% 68% 95.8% 
lymphadenopathy 76.7% 79% 87% 50% 84.9% 
 
Lab parameters:  HB, WBC count and platelet count is comparable 
with other studies 
 Lab parameter Manipur 
study[18] 
Other 
reviews[1,9,10] 
Present study 
HB <10 gms 96% 80-85% 90% 
WBC count >% 
>50,000 
20% 17%-25% 23.2% 
Platelet count 
<50,000   
73% 45% 65% 
 
Morphological classification: 
L1 and L2 are [54.7%, 45.3%] equally distributed in leukemic cases 
In contrast with the other reviews [4,5,16,18] where L1 morphology is 
more common 
 
Immunophenotyping: 
B cell in 65%, T cell in 35% and  was noted in this study. From other 
studies [9,10] T cell leukemia it is 15-22% supporting the evidence of higher 
incidence of T cell ALL in Indian population. T cell was associated with 
poor prognosis. 
Mediastinal lymphadenopathy is noted in 15% of the cases  against 
7% in other western studies [64] Renal involvement was noted in 9.5% of 
cases .18% in other reviews and associated with poor prognosis [50,64] 
.Parotid gland enlargement is noted in 21.9% of cases with poor prognosis 
[49] 
 
Rapidity of response: 
 Among 59 patients 29 cases [49.1%] showed disappearance of blasts 
in the peripheral smear with in seven days and 20 cases [33.8%] within 7-14 
days. 8 cases had persistence of blasts in 14-28 days of chemotherapy. 2 
cases had blasts in peripheral smear even after 1 month of induction therapy. 
More than 50% of cases showed poor response and poor prognosis. 
OUTCOME OF PATIENTS: 
Event free survival rate is lower in the present study than that of from 
other studies 
EFS Chennai 
study 2002 
[59] 
Tata 
memorial 
hospital 
1999[45] 
China 
study2005 
[12] 
National 
cancer 
institute 
2008[25] 
Present 
study 2008
2 years 41%    15.2% 
3 years 31%    10.8% 
4 years 18%  52.3%  5.4% 
5years  53%  85-88%  
T cell 
infancy 
Very high 
risk 
 45% 
                 
 62% 
10-30%   
<45% 
 
  
 
Overall survival rate is 35.8% which is about 59.8%, 57.6% in the 
vellore [27] and a china [12] study respectively. 
 
 
Outcome of death cases: 
21.5% of cases died before starting chemotherapy with high induction 
deaths. Cause of death was mainly bleeding in this study in contrast with 
many [22,24] other reviews where infection was the common cause of death           
 
Outcome of relapses: 
Relapse rates were comparable with Mumbai study and was more than that 
of AIIMS study and many western studies [42, 44]. 
 AIIMS 
study[37] 
China 
study[12] 
Mumbai 
study[45] 
Present study 
Relapse rate 17.1% 24.1% 29.9% 30.4% 
 
Most common site of relapse is bone marrow followed with testicular 
relapse which is 8.2% comparable with other reviews [9, 10]. Relapses were 
more common in male cases than females and most of them during 
maintenance period [41]. Only 30% are alive after relapse [9,10] 
RISK FACTORS ANALYSIS 
From study in Japan [58] age, sex and response to treatment were very 
significant factors. In FARLLE [57] study high WBC [p value 0.001], 
mediastinal mass [0.017] and the response [0.001] were significant 
RISK FACTORS ANALYSIS 
                            
FACTORS PRESENT 
STUDY  P 
VALUE 
CCG1978-1983 
AND 
[13]HAMMOND 
ET AL 
STUDY1986 
CHENNAI 
STUDY2002[59]
Age 0.170[ns] <0.0001  
Sex 0.245[ns] <0.0001  
WBC count 0.001[s] <0.0001 0.001 
platelet  0.0001[s] <0.0003 0.006 
Hemoglobin 0.225[ns] 0.53  
Liver 0.004[s] <0.0006 - 
Spleen 0.031[s] 0.19 - 
lymph node 0.001[s] 0.59 - 
med adenopathy 0.024[s] <0.0001 0.017 
BM blast 0.020[s] - - 
FAB 0.429[ns] <0.0004 - 
Rapidity of response 0.007[s] <0.0001 - 
            
LIMITATIONS OF THE STUDY 
1. Risk stratification was not done for cases in this study. 
2. Immuno phenotyping was done for only 9 cases. 
3. Cyto genetic analysis and minimal residual disease were not done for 
cases to predict the outcome. 
4. No separate regimen for T cell which is highly prevalent in India than 
in western countries and with poor prognosis. 
5. 8 cases were lost follow up in this study. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS       
 
1. There was a definite male preponderance with a peak age group was 
between 2-6 years 
2. Hepatomegaly was noted in 100% of cases. Splenomegaly in 95%and 
lymphadenopathy in 85% of the cases .CNS ivolvement in 4.1% of 
cases 
3. Severe extra medullary disease, renal involvement and parotid gland 
involvement were associated with poor prognosis 
4. WBC count at the time of presentation, platelet count, 
hepatosplenomegaly, lymphadenopathy, mediastinal 
lymphadenopathy, bone marrow blasts and the rapidity of the 
response were found to be statistically significant prognostic factors 
predicting the outcome and relapse  
5. There was no correlation between age, sex, hemoglobin and FAB 
morphology with the outcome 
6. This clinico-pathological risk scoring is simple. can be done in all 
peripheral hospitals as it does not require any advanced and costly 
techniques like immunophenotying and cytogenetics.It was found to 
be statistically significant 
7. Event free survival at 2,3 and 4 years are 15.2%,10.8%and 5.4% 
respectively and it is lower than that of other Indian and western 
reviews  
8. Relapses were noted in 30.4%of cases. 
9. Most common site was bone marrow. Testicular relapse was noted in 
8.2% 0f the cases  
10. Most of the relapses were noted in males and during maintenance 
phase 
11. 20% of deaths were before starting chemotherapy and 40% of the 
deaths before remission 
12. Bleeding was the cause of the death in nearly 80% of the cases 
13. Poor prognosis  noted in this study  could be due to high incidence of 
extramedullary disease, T cell leukemia, higher rates of death during 
induction, poor supportive care and lack bone marrow transplantation 
facilities in our set up 
 
 
 
 
 
RECOMMENDATIONS 
1.  Risk stratification will be useful to predict the long term outcome of 
the patients and segregate the high risk patients. This risk scoring with 
the available and possible datas can be very useful, low cast and 
applicable to all peripheral hospitals which are the treating places of 
leukemia in this less privileged country 
2. Immuno phenotyping and cytogenetic analysis should be done for all 
case to find out high risk cases. Those high risk cases can be referred 
to higher and specialized oncology centres 
3. Prednisolone response before chemotherapy and 14th day marrow after 
chemotherapy can predict the long term outcome when other 
prognostic factors losing the significance. 
4. Most of the relapses were during maintenance. So adding monthly 
vincristine and steroids may be helpful to prolong the remission in 
patients.  
5. Separate regimen for T cell patients may be useful to overcome the 
low event free survival rate in our Leukemia patients. 
6.  As nearly 70-80% of the relapses were occurred in males and all are 
early and intermediate relapses we can extend the duration of therapy 
from 2 years to 3 years for males as seen in other protocols of 
Leukemia.  
7. Bone marrow transplantation which is probably the only chance of 
cure for these patients must be made available once they enter 
remission at least for relapsed cases. 
8. Continuous supply of the drugs, good supportive care, adequate 
infection control practices and psychological supports should be made 
for all these patients to improve the outcome. 
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PROFORMA 
 
OUTCOME OF CHILDREN WITHACUTE LYMPHOBLASTIC 
LEUKEMIA IN GRH 
 
PROFORMA 
NAME :     ADDRESS: 
 
AGE  :      
 
SEX  :     OCCUPATION: 
DATE  OF DIAGNOSIS:    INCOME 
       PHONE NO 
PRESENT HISTORY :-   DURATION: 
 
H/O Fever / chills & rigor / night sweats. 
 
H/O Abdominal Distension / Abdominal Pain 
 
H/O Progressive pallor / easy fatigueability 
 
H/O Petechiae / Purpura / Eccymosis 
 
H/O Epistaxis / Haemetamesis / Haematuria / Gumbleed. 
 
H/O Bony swelling / Bony pain / Joint pain / restriction of joint movement 
 
H/O Neck swelling / generalized  Body swelling. 
 
H/O Breathlessness / cough / Stridor / wheeze. 
 
H/O loss of weight / Loss of Appetite / Failure to thrive. 
 
H/O head ache / Nausea / Vomiting / size of Head / Blurring of vision. 
 
H/O fits / Altered Sensorium / Coma. 
 
H/O Difficulty in speech / Gait abnormality 
 
H/O suggesting cranial (N) palsies / Paucity of movements 
 
H/O testicular swelling 
 
H/O Chest pain / Palpitation / Pedal  edema 
 
H/O Orbital swelling / diplopia / loss of vision 
 
H/O repeated blood transfusion 
 
Others  
PAST HISTORY: 
Previous H/O similar episode 
Previous H/O Hospitalization 
Previous H/O TB / Jaundice / other illness 
H/O RRI 
H/O Native Medicine 
ANTENATAL HISTORY :- 
 H/O drug intake  Yes / No 
 
 H/O irradiation  YES / NO 
 
BIRTH HISTORY :- 
 
NEONATAL HISTORY :- 
 
DEVELOPMENTAL HISTORY :- 
 
IMMUNISATION HISTORY :- 
 
FAMILY HISTORY :- 
 H/O any Leukemia / other cancers in the family 
 
RISK FACTORS :- 
Environmental Factors 
  1.   Ionizing radiation 
  2.   Toxic Chemicals / Pesticide exposure 
Immuno Defficency states :- 
  1.   Down’s syndrome 
  2.   Bloom’s syndrome 
  3.   fredrick’s ataxia 
  4.   Others 
GENERAL EXAMINATION 
Mental status 
General Condition 
Febrile / Afebrile 
Respiratory status 
Hydration 
Pallor  
Icterus / cyanosis / clubbing 
Dental carries / oral ulcer 
Lymphadenopathy –  1 cervical 
    2. axillary 
    3. inguinal 
bonytenderness / bony swelling / joint pain RR 
 
Petechiae / Purpura / Eccymosis 
ANTHROPOMETRY   VITALS 
 HC    HR 
 CC    RR  
 HT    BP 
 WT 
 AC    TEMP 
SYSEMIC EXMINATION 
I.  ABDOMEN : 
 INSPECTION 
   Shape of the abdomen 
   Movement with respiration 
   Mass dilated veins, pulsations 
 PALPATION ;- 
   Tenderness 
   Liver :-    Spleen :- 
    Size      Size 
    Span 
    Firm / soft     Consistency 
    Surface 
        
   Renomegaly :-   Freefluid :- 
 PERCUSSION :- 
 
 AUSCULATION :- 
 
 GENITALS :- 
 
II. CARDIO VASCULAR SYSTEM; 
  
  apical impulse 
  heart sounds 
  murmur     
III. RESPIRATORY SYSTEM :- 
  Trachea Position 
  Size / shape of the chest 
  Type of respiration 
  Chest expansion 
  Percussion note 
  Auscultation 
IV. CENTRAL NERVOUS SYSTEM :- 
  Higher function 
 
  Cranial (N) Examination 
   
  Motor System 
 
 
  Sensory System 
 
  Cerebellar System 
 
  Spine & Cranium 
 
  Gait 
 
  Fundus 
INVESTIGATIONS :- 
  URINE : Alb 
    Sug 
    Deposits 
  BLOOD ; HB % 
    TC 
    DC 
  PLATELER COUNT 
    Bleeding time  
    Clotting Time 
    Blood grouping and typing 
COMPLETE HAEMOGRAM 
 
 
 
 
PERIPHEAL SMEAR  Pathology No: 
 
 
 
BONE MARROW STUDY Pathology No 
: 
 
 
IMMUNO PHENO TYPING 
 
 
 CYTO GENETIC STUDY 
 
 
BLOOD 
 Urea      CSF; 
 Sugar       cells 
 Serum, Creatine 
 Serum Uric Acid 
 Serum Amylase 
LFT 
 Bilirubin  
 Proteins 
 SGOT   SGPT   Alkaline Phosphatase 
 LDH     
HBSAG,  
HIV 
 Calcium,    phosphorus   
 
X – RAY CHEST 
 
ULTRA SOUND ABDOMEN 
 
ECG 
ECHO 
 
BLOOD CULTURE 
 
URINE CULTURE 
 
CT SCAN BRAIN / CHEST / ABDOMEN 
 
DIAGNOSIS 
 
 
 
 
 
 
 
    
        
 
 
 
 
 
 
 
 
 
 ABBREVIATIONS USED  
 
ALL     - Acute lymphatic leukemia  
AML     - Acute myeloid leukemia 
ATRA-C    - Cytosine arabinoside  
CNS     - Central nervous system 
CSF     - Cerebro Spinal fluid. 
EFS     - Event Free survival  
FAB     - French American British 
HB     - Hemoglobin 
Ig     - Immunoglobulin 
I.T     - Intrathecal 
MTX     - Methotrexate 
MRD     - Minimal Residual Disease. 
NCI     -  National Cancer Institute 
PAS     - Periodic Acid Schiff staining 
POG     - Paediatric Oncology group 
WHO     -   World Health Organization 
WBC     - White Blood 
 
 
S.No Name Date Outcome Age Sex WBC Platelet Hb Liver SpleenLymph NodeMedia Lym FAB BM Blast Response Risk Score
1 pavithra 9.6.05 1 9 1 4400 52000 4.5 2 0 0 0 0 72 1 7
2 balasubram3.2.05 1 7 0 10200 60000 3.4 4 7 0 0 0 70 0 10
3 nimekalai 31.7.05 1 6 1 8400 150000 10 2 2 0 0 0 72 0 3
4 balamuruga12.10.05 1 10 0 4600 150000 9 5 10 1 0 0 42 0 5
5 riyaz 16.5.05 2 6 0 6000 70000 9.8 2 1 1 0 0 65 1 7
6 balaji 6.5.05 4 5 0 12400 20000 3.8 3 3 0 0 0 90 1 11
7 sabana 3.3.05 1 7 1 110000 60000 6 6 5 0 0 0 70 0 7
9 sandhya 11.2.05 4 5 1 18000 20000 4.5 4 8 2 0 1 90 0 13
10 b.thanush 9.4.05 3 8 months 0 60000 20000 3.8 8 10 1 0 0 95 15
11 sandhya 13.4.05 4 9 1 68000 20000 3.2 10 12 1 0 0 95 1 14
12 isravel 10.4.05 3 4.5 0 11600 90000 4 5 7 2 0 1 95 15
13 sangeetha 7.5.05 3 7 1 21000 20000 5 4 2 1 0 1 71 1 10
14 roselline 12.7.05 4 10 1 70000 60000 6 8 0 1 0 1 90 1 11
15 monika 3.12.05 4 9 1 28000 20000 3.8 6 7 2 0 1 95 1 16
16 suganya 4.8.05 3 11 1 18500 20000 4 8 9 2 0 1 95 15
17 munitaraj 30.12.05 4 10 0 34000 30000 4.5 6 8 2 0 0 90 0 14
18 abdul 11.1.05 1 9 1 19500 60000 9.2 2 1 2 0 0 45 0 8
19 hari 14.1.06 1 3 0 8200 180000 6.8 3 2 0 0 0 35 0 4
20 m.selvaraj 8.2.06 2 5.5 0 6400 20000 6.2 4 0 2 0 0 80 1 9
21 sneka 20.5.06 1 4 1 9000 90000 4.6 2 0 0 0 90 0 6
22 rajesh 23.6.06 1 7 0 28000 150000 8 4 4 2 0 1 95 0 8
23 stalin 28.9.06 1 10 0 6600 30000 8 6 3 1 0 0 85 0 7
24 sabari 18.10.06 2 7 0 700 45000 8.9 2 1 0 0 55 1 6
25 vigneswara30.6.06 2 1.5 0 6400 20000 2.8 4 2 1 0 1 60 0 10
26 baskar 11.9.06 3 4 0 21000 20000 2.8 4 3 1 0 0 95 0 11
27 manoj 9.1.06 3 2.5 0 6000 45000 5 11 8 1 0 0 80 2 11
28 arun 10.12.06 3 4.5 0 20000 20000 4.3 8 10 2 0 0 90 0 15
29 y.bhrathi 3.6.06 3 3 1 18000 20000 3.8 6 7 2 0 1 60 1 14
30 mahalaksh 17.1.06 3 2 1 60000 20000 4.6 8 4 2 0 0 95 2 15
31 mariajency 17.3.06 3 5 1 18000 60000 6.2 8 4 2 0 0 90 1 11
32 rektchi 24.1.07 4 4 1 14000 45000 6.8 8 4 2 0 0 90 1 11
33 seetharama21.2.07 1 4.5 0 20000 60000 8.7 1 2 0 0 70 0 4
34 vinohini 9.3.07 4 4 1 16000 45000 5.6 5 8 1 0 0 90 2 12
35 priya 21.3.07 1 11 1 35500 100000 3.6 6 3 1 0 0 70 0 11
36 davin 9.3.07 1 2 0 4600 20000 6.2 3 4 0 0 0 35 0 6
37 mohan 17.7.07 1 3 0 11000 20000 4 2 2 0 1 70 2 12
S.No Name Date Outcome Age Sex WBC Platelet Hb Liver SpleenLymph NodeMedia Lym FAB BM Blast Response Risk Score
38 prasanth 20.12.07 1 8 0 200000 20000 10 8 10 2 1 1 95 2 17
39 pandeswar 22.4.07 2 4 0 66400 20000 5.8 6 10 2 1 1 95 2 19
40 k.sundram 20.12.07 1 7 0 88000 52000 3.4 6 10 1 0 1 95 0 12
41 priya 25.6.07 3 3.5 1 92000 17000 4.6 6 6 1 0 1 75 0 13
42 staleeswara24.8.07 3 5 0 28000 45000 6 8 6 2 1 0 90 2 15
43 aagathesw 16.2.07 3 3 0 95000 20000 3.8 3 4 2 0 0 95 13
44 kowsalya 11.10.07 3 1.5 0 14650 20000 5.2 4 5 1 0 1 90 1 14
45 chakkarava19.10.07 4 4 0 22000 12000 2.8 8 9 2 0 1 95 13
46 t.selvam 11.2.08 1 8 0 7200 120000 3.6 4 2 1 0 0 75 0 7
47 vignesh 19.2.08 1 8 0 2900 72000 5.9 2 2 2 0 1 85 2 11
48 kowsalya 19.5.08 1 8 1 24000 20000 6.8 6 7 1 0 1 85 1 12
49 kumaran 2.5.08 3 3 0 20000 20000 6.6 2 2 1 0 0 85 1 10
50 simran 14.4.08 1 8 1 3500 20000 5.5 5 3 1 0 1 82 0 9
51 swedha 9.6.08 1 5 1 200000 20000 3.5 6 6 1 0 1 85 2 15
52 saran 24.1.08 3 1.5 1 18000 20000 4.2 6 3 1 0 0 96 12
53 sairabanu 25.6.08 1 8 0 45000 20000 3.6 6 6 2 0 1 90 0 15
54 suresh 25.3.08 3 11 1 139000 13000 7.8 3 3 0 1 90 0 11
55 punitha 11.3.08 3 2.5 1 24500 20000 4 8 9 1 0 1 95 13
56 stephina 16.7.08 3 6 1 8400 25000 9 4 4 1 0 0 75 6
57 prithvi 30.11.04 2 4.5 0 145000 90000 6.8 6 4 1 0 0 85 9
58 kanimozhi 30.10.04 1 4 1 6000 20000 7.8 3 2 0 0 0 95 0 7
59 thilagaraj 23.2.04 1 12 0 35000 60000 9.2 2 1 1 1 0 45 0 8
60 marisree 2.2.04 1 10 0 25000 150000 5.6 4 3 1 0 1 85 0 8
61 vignesh 6.8.04 1 3.5 1 18000 120000 6.8 3 4 0 0 0 80 0 5
62 pavithra 15.7.04 4 7 0 100000 45000 3.4 10 16 2 1 0 95 1 18
63 a.babu 18.2.04 4 10 1 6600 20000 4.8 9 10 1 0 1 90 0 15
64 harikaran 25.6.04 3 6 months 0 25000 20000 6.2 8 10 2 0 1 95 1 14
65 muthu priya24.2.04 4 8 0 28000 18000 11.3 9 14 2 1 1 80 1 12
66 siva 24.6.04 3 1.5 0 18200 40000 7.6 8 8 2 1 0 90 16
67 padiyan 24.5.04 3 10 0 28000 45000 8.8 8 11 1 0 0 85 11
68 balasubram13.6.04 4 3 0 58000 20000 4.2 8 6 0 1 95 1 15
69 kalimuthu 8.10.04 4 12 0 44000 20000 6.4 6 10 2 1 1 75 2 16
70 masanam 8.11.04 4 8 1 38000 40000 3.8 7 8 2 0 1 90 1 15
71 aswin 6.8.08 3 2.5 1 58000 20000 3.2 8 12 1 0 1 95 14
72 sandhiya 7.9.08 3 8 1 68000 250000 2 9 9 2 1 0 95 15
73 apsana 8.7.04 3 2.5 0 35000 150000 3.6 8 9 2 1 1 90 15
e
e
